This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. DOMH, FBIO, BOLT, SABS, CRIS, MTEM, AMGN, GILD, VRTX, and REGNShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Dominari (DOMH), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Dominari Fortress Biotech Bolt Biotherapeutics SAB Biotherapeutics Curis Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Cytori Therapeutics (NASDAQ:CYTX) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment. Which has more risk and volatility, CYTX or DOMH? Cytori Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Is CYTX or DOMH more profitable? Dominari has a net margin of -180.22% compared to Cytori Therapeutics' net margin of -242.60%. Dominari's return on equity of -32.89% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% Dominari -180.22%-32.89%-29.47% Does the media favor CYTX or DOMH? In the previous week, Dominari had 2 more articles in the media than Cytori Therapeutics. MarketBeat recorded 2 mentions for Dominari and 0 mentions for Cytori Therapeutics. Dominari's average media sentiment score of 1.23 beat Cytori Therapeutics' score of 0.00 indicating that Dominari is being referred to more favorably in the news media. Company Overall Sentiment Cytori Therapeutics Neutral Dominari Positive Do insiders and institutionals hold more shares of CYTX or DOMH? 2.6% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 0.7% of Cytori Therapeutics shares are owned by company insiders. Comparatively, 33.0% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, CYTX or DOMH? Cytori Therapeutics has higher earnings, but lower revenue than Dominari. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M4.76-$12.63MN/AN/ADominari$18.15M3.87-$22.88M-$2.39-2.00 Does the MarketBeat Community favor CYTX or DOMH? Cytori Therapeutics received 442 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformCytori TherapeuticsOutperform Votes44273.67% Underperform Votes15826.33% DominariN/AN/A SummaryDominari beats Cytori Therapeutics on 8 of the 12 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.46M$4.35B$5.46B$7.81BDividend YieldN/A46.48%5.43%4.30%P/E RatioN/A30.7422.2518.42Price / Sales4.7653.01391.10101.46Price / CashN/A51.0838.1834.62Price / Book2.256.146.674.19Net Income-$12.63M$68.15M$3.21B$247.97M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$0.79-6.5%N/A-47.3%$17.46M$3.67M0.0037Gap DownDOMHDominari0.8984 of 5 stars$4.29+5.4%N/A+77.4%$46.82M$18.15M-1.114FBIOFortress Biotech2.5961 of 5 stars$1.51+0.3%$21.00+1,295.3%-4.7%$44.45M$57.68M-0.49170Gap UpBOLTBolt Biotherapeutics2.8379 of 5 stars$0.37+7.9%$1.13+205.7%-66.4%$14.11M$7.69M-0.2290News CoveragePositive NewsSABSSAB Biotherapeutics3.2156 of 5 stars$1.36-4.6%$11.40+737.6%-56.4%$12.64M$2.24M-0.37140Gap UpCRISCuris2.2777 of 5 stars$1.33+1.9%$21.00+1,484.9%-88.8%$11.25M$10.91M-0.1760Analyst ForecastGap UpMTEMMolecular TemplatesN/A$0.00flatN/AN/A$1,000.00$23.48M0.00260AMGNAmgen4.6162 of 5 stars$277.41+1.4%$310.57+12.0%+4.3%$149.15B$33.42B36.7425,200Upcoming EarningsAnalyst ForecastAnalyst RevisionPositive NewsGILDGilead Sciences4.5026 of 5 stars$105.90+1.5%$106.92+1.0%+58.1%$131.86B$28.75B286.2017,000Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionNews CoverageGap DownVRTXVertex Pharmaceuticals4.051 of 5 stars$490.51+2.7%$514.91+5.0%+24.2%$125.96B$11.02B-222.964,800Analyst ForecastAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.804 of 5 stars$581.15+3.5%$950.76+63.6%-32.3%$63.53B$14.20B15.1811,900Upcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies DOMH Competitors FBIO Competitors BOLT Competitors SABS Competitors CRIS Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
